Is using atracurium (non‑depolarizing neuromuscular blocker) together with midazolam (benzodiazepine) an appropriate rapid‑sequence intubation strategy in the emergency department?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Atracurium + Midazolam for ED Intubation: Not Recommended

Atracurium combined with midazolam is NOT an appropriate rapid-sequence intubation (RSI) strategy in the emergency department. While both agents can be used for intubation, this specific combination has significant limitations that make it suboptimal compared to standard RSI approaches.

Why This Combination Falls Short

The Atracurium Problem

Atracurium is too slow for true RSI. The drug has an onset time of 3-5 minutes to achieve maximum neuromuscular blockade 1, which is far too prolonged for emergency airway management. Recent evidence confirms that even at high doses (1 mg/kg), atracurium provides only 51.4% success rates for intubation within one minute 2. This delay leaves patients vulnerable to:

  • Prolonged apnea time
  • Increased aspiration risk
  • Inadequate intubating conditions during the critical first minute

The 2023 Society of Critical Care Medicine guidelines for RSI recommend either rocuronium or succinylcholine as the neuromuscular blocking agents of choice 3, 4. These agents achieve paralysis within 45-60 seconds, which is essential for RSI. Atracurium is notably absent from current RSI recommendations.

The Midazolam Limitation

Midazolam alone is inadequate as an induction agent for RSI. The 2008 AAP pediatric guidelines note that when midazolam is used as an adjunct for intubation, you must "allow sufficient time (2-3 minutes) for midazolam to take effect before administration of muscle relaxant" 5. This contradicts the fundamental principle of RSI, which requires rapid succession of medications.

At the dose needed for RSI (0.2 mg/kg), midazolam has:

  • Slower onset than preferred induction agents (etomidate, ketamine, propofol)
  • Less predictable hemodynamic effects
  • Higher risk of respiratory depression when combined with other sedatives 5

What You Should Use Instead

Recommended RSI Combinations

For most ED patients:

  • Etomidate (0.3 mg/kg) + Rocuronium (1.2 mg/kg) OR
  • Etomidate (0.3 mg/kg) + Succinylcholine (1.5 mg/kg)

Recent large-scale data suggests succinylcholine may be associated with lower 60-day mortality compared to rocuronium (30.1% vs 33.4%, RR 0.901) 6, though both are acceptable choices.

For hemodynamically unstable patients:

  • Ketamine (1-2 mg/kg) + Rocuronium (1.2 mg/kg) OR
  • Ketamine (1-2 mg/kg) + Succinylcholine (1.5 mg/kg)

Current evidence suggests etomidate may produce less hypotension than ketamine in shock/sepsis, though this remains an area of active investigation 7.

The Neuromuscular Blocker Choice

Rocuronium (1.2 mg/kg) and succinylcholine (1.5 mg/kg) are the only acceptable paralytics for RSI 3, 4. The 2020 European guidelines confirm that high-dose rocuronium (>0.9 mg/kg) provides intubating conditions comparable to succinylcholine 8.

Choose succinylcholine when:

  • Rapid recovery is desired (3-5 minute duration)
  • No contraindications exist (hyperkalemia, burns >24 hours old, neuromuscular disease, malignant hyperthermia history)

Choose rocuronium when:

  • Succinylcholine is contraindicated
  • Longer paralysis duration is acceptable (45-60 minutes)
  • Sugammadex reversal is available if needed

Critical Evidence on Neuromuscular Blockade

Using a neuromuscular blocking agent during RSI significantly improves outcomes. A 2012 multicenter study of 454 emergent intubations found that NMBA use was associated with:

  • Lower prevalence of hypoxemia (10.1% vs 17.4%, p=0.022)
  • Fewer procedure-related complications (3.1% vs 8.3%, p=0.012)
  • Better intubating conditions 9

The 2020 European guidelines meta-analysis showed that without a neuromuscular blocker, 24.6% of patients had poor intubating conditions versus only 4.1% with an NMBA 8.

When Atracurium Might Be Considered

Atracurium has a limited role in specific scenarios:

ICU prolonged paralysis: For patients requiring sustained neuromuscular blockade (mechanical ventilation >24 hours), atracurium or cisatracurium may be preferred due to organ-independent elimination 10. Typical infusion rates are 11-13 mcg/kg/min 1.

Patients with renal/hepatic failure: Atracurium undergoes Hofmann elimination and ester hydrolysis, making it suitable when other agents would accumulate 1. However, this advantage is irrelevant for single-dose RSI.

NOT for emergency RSI: The slow onset makes atracurium inappropriate for rapid airway control.

Common Pitfalls to Avoid

  1. Don't confuse ICU paralysis with RSI: Atracurium's role in prolonged ICU paralysis does not translate to emergency intubation
  2. Don't underdose rocuronium: Use 1.2 mg/kg for RSI, not the standard 0.6 mg/kg surgical dose
  3. Don't delay intubation waiting for paralysis: With proper agents, you should be intubating within 45-60 seconds
  4. Don't forget post-intubation sedation: Regardless of induction agent, establish continuous sedation immediately after successful intubation 3

The Bottom Line

Use etomidate or ketamine with either rocuronium (1.2 mg/kg) or succinylcholine (1.5 mg/kg) for ED rapid-sequence intubation 3, 4, 7. The atracurium + midazolam combination lacks the rapid onset required for safe RSI and is not supported by current evidence or guidelines. Reserve atracurium for ICU patients requiring prolonged neuromuscular blockade, not emergency airway management.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.